We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.
- Authors
Hart, Mary Kate; Saviolakis, George A.; Welkos, Susan L.; House, Robert V.
- Abstract
The development of vaccines for microorganisms and bacterial toxins with the potential to be used as biowarfare and bioterrorism agents is an important component of the US biodefense program. DVC is developing two vaccines, one against inhalational exposure to botulinumneurotoxins A1 and B1 and a second for Yersinia pestis, with the ultimate goal of licensure by the FDA under the Animal Rule. Progress has been made in all technical areas, including manufacturing, nonclinical, and clinical development and testing of the vaccines, and in assay development. The current status of development of these vaccines, and remaining challenges are described in this chapter.
- Subjects
DRUG development; BOTULINUM toxin; UNITED States. Food &; Drug Administration; BIOTERRORISM; BIOSECURITY; VACCINE trials; BACTERIAL toxins; YERSINIA pestis
- Publication
Advances in Preventive Medicine, 2012, p1
- ISSN
2090-3480
- Publication type
Article
- DOI
10.1155/2012/731604